Area of research
Immunology · Oncology
Research interest
Research interests include Immunotherapy and Immune Responses, T-cell and B-cell Immunology, Cancer Immunotherapy and Biomarkers, and Monoclonal and Polyclonal Antibodies Research.
Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4
B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma
Clinical and Translational Significance of Basophils in Patients with Cancer
Enriched circulating and tumor-resident TGF-β <sup>+</sup> regulatory B cells in patients with melanoma promote FOXP3 <sup>+</sup> Tregs
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies
A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states
Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types
Skin resident memory CD8+ T cells are phenotypically and functionally distinct from circulating populations and lack immediate cytotoxic function
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Enhancement of cutaneous immunity during aging by blocking p38 mitogen-activated protein (MAP) kinase–induced inflammation
B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment
IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin
PAK4 suppresses PDZ-RhoGEF activity to drive invadopodia maturation in melanoma cells
Revisiting the role of B cells in skin immune surveillance
Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma
Effects of <i>BRAF</i> Mutations and <i>BRAF</i> Inhibition on Immune Responses to Melanoma
Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review)
IgG4 subclass antibodies impair antitumor immunity in melanoma
Varicella Zoster–Specific CD4+Foxp3+ T Cells Accumulate after Cutaneous Antigen Challenge in Humans
Investigation of the cutaneous response to recall antigen in humans<i>in vivo</i>